Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

131.65 +0.81 (+0.62%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

May 01, 2026

From Gilead Sciences, Inc.

Via Business Wire

U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

April 29, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

April 28, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

April 22, 2026

From Gilead Sciences, Inc.

Via Business Wire

PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access

April 14, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

April 07, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Extends Tender Offer to Acquire Arcellx

April 01, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

March 23, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

March 02, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

February 25, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences to Present at Upcoming Investor Conferences

February 23, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

February 23, 2026

From Arcellx, Inc.

Via Business Wire

Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

February 17, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

February 10, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

February 10, 2026

From Gilead Sciences, Inc.

Via Business Wire

FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma

February 06, 2026

From Gilead Sciences, Inc.

Via Business Wire

Crossroads4Hope Kicks Off Its 25th Year of Caring with the Launch of Free Breast and Colorectal Cancer Resources for Patients and Families Nationwide

February 02, 2026

Via PRLog

The Commonwealth Club Honors Black History Month With Event Featuring Top Black Leaders in AI & Biopharma Discussing the Future of Healthcare

January 29, 2026

Via Get News

Topics Artificial Intelligence

Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

January 27, 2026

From Gilead Sciences, Inc.

Via Business Wire

New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer

January 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences to Present at Upcoming Investor Conference

December 22, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

December 22, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

December 19, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

December 18, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

December 15, 2025

From Gilead Sciences, Inc.

Via Business Wire

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

December 12, 2025

Issued on behalf of Oncolytics Biotech Inc.

From Equity Insider

Via GlobeNewswire

Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer

December 09, 2025

From Gilead Sciences, Inc.

Via Business Wire

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

December 07, 2025

From Gilead Sciences, Inc.

Via Business Wire

Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

December 06, 2025

From Gilead Sciences, Inc.

Via Business Wire

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma

December 06, 2025

From Gilead Sciences, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.